Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 21c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $316.24 -1.97%
EPS Growth %: +24.4%
Financial Fact:
Total revenues: 21.62M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: +24.4%
Financial Fact:
Total revenues: 21.62M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.20), $0.21 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $5.7 million versus the consensus estimate of $5.9 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ligand Pharma (LGND) PT Raised to $388 at BofA Securities
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Northern Technologies (NTIC) Misses Q3 EPS by 12c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
